Market research
SLGL Sol Gel Technologies Ltd
NASDAQ USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 210M
- P/E ratio
- Not available
- Analyst target
- 152.5
- Dividend yield
- Not available
- Beta
- 1.15
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- IL0011417206
- Market cap
- 210M
- P/E ratio
- Not available
- Analyst target
- 152.5
- Dividend yield
- Not available
- Beta
- 1.15
About
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Research context
Sol Gel Technologies Ltd appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the SLGL discussion.
5 years, 6 months ago
Sol-Gel Technologies Ltd is currently in a long term uptrend where the price is trading 15.5% above its 200 day moving average.
From a valuation standpoint, the stock is 97.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.7.
Sol-Gel Technologies Ltd's total revenue sank by 48.8% to $2M since the same quarter in the previous year.
Its net income has increased by 1.7% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 4.1% to $-10M since the same quarter in the previous year.
Based on the above factors, Sol-Gel Technologies Ltd gets an overall score of 4/5.